VJHemOnc is committed to improving our service to you

EHA 2019 | Venetoclax with bortezomib/dexamethasone: phase 3 BELLINI results in R/R myeloma

VJHemOnc is committed to improving our service to you

Shaji Kumar

Shaji Kumar from the Mayo Clinic, Rochester, MN, discusses the data he presented as a late-breaking abstract at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. Dr Kumar presents the results of the Phase 3 trial investigating venetoclax in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. This press briefing was recorded at the 24th Congress of the EHA 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter